🚀 VC round data is live in beta, check it out!
Sangamo Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sangamo Therapeutics and similar public comparables like Medivir, Verrica Pharmaceuticals, Recce Pharmaceuticals, Assertio Therapeutics and more.
Sangamo Therapeutics Overview
About Sangamo Therapeutics
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Founded
1995
HQ
Employees
183
Website
Financials (LTM)
EV
$119M
Sangamo Therapeutics Financials
Sangamo Therapeutics reported last 12-month revenue of $48M and negative EBITDA of ($95M).
In the same LTM period, Sangamo Therapeutics generated $47M in gross profit, ($95M) in EBITDA losses, and had net loss of ($108M).
Revenue (LTM)
Sangamo Therapeutics P&L
In the most recent fiscal year, Sangamo Therapeutics reported revenue of $40M and EBITDA of ($100M).
Sangamo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $48M | XXX | $40M | XXX | XXX | XXX |
| Gross Profit | $47M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($95M) | XXX | ($100M) | XXX | XXX | XXX |
| EBITDA Margin | (197%) | XXX | (254%) | XXX | XXX | XXX |
| EBIT Margin | (220%) | XXX | (273%) | XXX | XXX | XXX |
| Net Profit | ($108M) | XXX | ($123M) | XXX | XXX | XXX |
| Net Margin | (225%) | XXX | (311%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sangamo Therapeutics Stock Performance
Sangamo Therapeutics has current market cap of $113M, and enterprise value of $119M.
Market Cap Evolution
Sangamo Therapeutics' stock price is $0.27.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $119M | $113M | 4.0% | XXX | XXX | XXX | $-0.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSangamo Therapeutics Valuation Multiples
Sangamo Therapeutics trades at 2.5x EV/Revenue multiple, and (1.3x) EV/EBITDA.
EV / Revenue (LTM)
Sangamo Therapeutics Financial Valuation Multiples
As of April 21, 2026, Sangamo Therapeutics has market cap of $113M and EV of $119M.
Equity research analysts estimate Sangamo Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sangamo Therapeutics has a P/E ratio of (1.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $113M | XXX | $113M | XXX | XXX | XXX |
| EV (current) | $119M | XXX | $119M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | (1.3x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/EBIT | (1.1x) | XXX | (1.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | — | XXX | XXX | XXX |
| P/E | (1.0x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/FCF | (1.4x) | XXX | (1.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sangamo Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sangamo Therapeutics Margins & Growth Rates
Sangamo Therapeutics' revenue in the last 12 month grew by 80%.
Sangamo Therapeutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.
Sangamo Therapeutics' rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sangamo Therapeutics' rule of X is 114% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sangamo Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 80% | XXX | 71% | XXX | XXX | XXX |
| EBITDA Margin | (197%) | XXX | (254%) | XXX | XXX | XXX |
| EBITDA Growth | (58%) | XXX | (58%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 8% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 114% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 88% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 232% | XXX | 285% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 373% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sangamo Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sangamo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Medivir | XXX | XXX | XXX | XXX | XXX | XXX |
| Verrica Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Recce Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Assertio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Coya Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sangamo Therapeutics M&A Activity
Sangamo Therapeutics acquired XXX companies to date.
Last acquisition by Sangamo Therapeutics was on XXXXXXXX, XXXXX. Sangamo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sangamo Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSangamo Therapeutics Investment Activity
Sangamo Therapeutics invested in XXX companies to date.
Sangamo Therapeutics made its latest investment on XXXXXXXX, XXXXX. Sangamo Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sangamo Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sangamo Therapeutics
| When was Sangamo Therapeutics founded? | Sangamo Therapeutics was founded in 1995. |
| Where is Sangamo Therapeutics headquartered? | Sangamo Therapeutics is headquartered in United States. |
| How many employees does Sangamo Therapeutics have? | As of today, Sangamo Therapeutics has over 183 employees. |
| Who is the CEO of Sangamo Therapeutics? | Sangamo Therapeutics' CEO is Alexander Donald Macrae. |
| Is Sangamo Therapeutics publicly listed? | Yes, Sangamo Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Sangamo Therapeutics? | Sangamo Therapeutics trades under SGMO ticker. |
| When did Sangamo Therapeutics go public? | Sangamo Therapeutics went public in 2000. |
| Who are competitors of Sangamo Therapeutics? | Sangamo Therapeutics main competitors are Medivir, Verrica Pharmaceuticals, Recce Pharmaceuticals, Assertio Therapeutics. |
| What is the current market cap of Sangamo Therapeutics? | Sangamo Therapeutics' current market cap is $113M. |
| What is the current revenue of Sangamo Therapeutics? | Sangamo Therapeutics' last 12 months revenue is $48M. |
| What is the current revenue growth of Sangamo Therapeutics? | Sangamo Therapeutics revenue growth (NTM/LTM) is 80%. |
| What is the current EV/Revenue multiple of Sangamo Therapeutics? | Current revenue multiple of Sangamo Therapeutics is 2.5x. |
| Is Sangamo Therapeutics profitable? | No, Sangamo Therapeutics is not profitable. |
| What is the current EBITDA of Sangamo Therapeutics? | Sangamo Therapeutics has negative EBITDA and is not profitable. |
| What is Sangamo Therapeutics' EBITDA margin? | Sangamo Therapeutics' last 12 months EBITDA margin is (197%). |
| What is the current EV/EBITDA multiple of Sangamo Therapeutics? | Current EBITDA multiple of Sangamo Therapeutics is (1.3x). |
| What is the current FCF of Sangamo Therapeutics? | Sangamo Therapeutics' last 12 months FCF is ($86M). |
| What is Sangamo Therapeutics' FCF margin? | Sangamo Therapeutics' last 12 months FCF margin is (180%). |
| What is the current EV/FCF multiple of Sangamo Therapeutics? | Current FCF multiple of Sangamo Therapeutics is (1.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.